AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · Real-Time Price · USD
0.3269
+0.0369 (12.72%)
Sep 11, 2026, 4:00 PM EDT - Market closed
AEON Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
16.31M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
AEON News
- 4 days ago - Aeon Biopharma announces results from ABP-450 pilot forced degradation study - TheFly
- 4 days ago - AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX® - GlobeNewsWire
- 4 days ago - Aeon Biopharma initiated with a Buy at Laidlaw - TheFly
- 13 days ago - AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference - GlobeNewsWire
- 20 days ago - Aeon Biopharma designates Paul Lee as acting chief regulatory officer - TheFly
- 20 days ago - AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer - GlobeNewsWire
- 25 days ago - AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX® - GlobeNewsWire
- 4 weeks ago - Aeon Biopharma price target lowered to $1.20 from $5 at H.C. Wainwright - TheFly